The study of a novel CDK8 inhibitor E966-0530–45418 that inhibits prostate cancer metastasis in vitro and in vivo

Author:

Ho Tai-Yuan,Sung Ting-Yi,Pan Shiow-Lin,Huang Wei-JanORCID,Hsu Kai-Cheng,Hsu Jui-Yi,Lin Tony Eight,Hsu Chia-Ming,Yang Chia-RonORCID

Funder

National Science and Technology Council

Ministry of Science and Technology, Taiwan

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference36 articles.

1. World Cancer Research Fund International, Prostate cancer statistics. 〈https://www.wcrf.org/cancer-trends/prostate-cancer-statistics/〉 (assessed 23 March 2022).

2. CDK8-novel therapeutic opportunities;Menzl;Pharmaceuticals,2019

3. American Cancer Society, Key Statistics for Prostate Cancer. 〈https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html〉 (revised on 12 January 2023).

4. Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer;Constantin;Oncogene,2022

5. The mediator complex: a central integrator of transcription;Allen;Nat. Rev. Mol. Cell Biol.,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3